ethyl {(1,3-benzothiazol-2-ylmethyl)[5-(2,6-dimethoxyphenyl)-1,2,4-triazin-3-yl]amino}acetate | 1203605-43-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: ethyl {(1,3-benzothiazol-2-ylmethyl)[5-(2,6-dimethoxyphenyl)-1,2,4-triazin-3-yl]amino}acetate
• 英文别名: ethyl {(1,3-benzothiazol-2-ylmethyl)[5-(2,6-dimethoxyphenyl)-1,2,4-triazin-3-yl]amino} acetate；Ethyl 2-[1,3-benzothiazol-2-ylmethyl-[5-(2,6-dimethoxyphenyl)-1,2,4-triazin-3-yl]amino]acetate；ethyl 2-[1,3-benzothiazol-2-ylmethyl-[5-(2,6-dimethoxyphenyl)-1,2,4-triazin-3-yl]amino]acetate
• CAS: 1203605-43-9
• 化学式: C₂₃H₂₃N₅O₄S
• 分子量: 465.533
• InChiKey: APZLNHGHRVIBJX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  33
• 可旋转键数：
  10
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  128
• 氢给体数：
  0
• 氢受体数：
  10

反应信息

• 作为反应物：
  描述：

  ethyl {(1,3-benzothiazol-2-ylmethyl)[5-(2,6-dimethoxyphenyl)-1,2,4-triazin-3-yl]amino}acetate 在 水 、 lithium hydroxide 、 盐酸 作用下， 以 四氢呋喃 、 水 为溶剂， 以44%的产率得到{(1,3-benzothiazol-2-ylmethyl)[5-(2,6-dimethoxyphenyl)-1,2,4-triazin-3-yl]amino}acetic acid
  参考文献：
  名称：

  New 1,2,4-triazine derivatives and biological applications thereof

  摘要：

  这项发明涉及公式(I)的新1,2,4-三嗪衍生物： 其中A、B、R2和Y在申请中有定义， 它们的制备和中间体，它们作为药物和药物组合物的用途以及含有它们的关联物。 公式(I)的化合物能够抑制细菌七糖合成。

  公开号：

  EP2141164A1
• 作为产物：
  描述：

  2,6-二甲氧基苯乙酮 在 亚硝酸特丁酯 、 phenyltrimethylammonium tribromide 、 溶剂黄146 、 N,N-二异丙基乙胺 、 copper dichloride 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 乙腈 为溶剂， 反应 99.0h， 生成 ethyl {(1,3-benzothiazol-2-ylmethyl)[5-(2,6-dimethoxyphenyl)-1,2,4-triazin-3-yl]amino}acetate
  参考文献：
  名称：

  Novel HldE-K Inhibitors Leading to Attenuated Gram Negative Bacterial Virulence

  摘要：

  We report here the optimization of an HldE kinase inhibitor to low nanomolar potency, which resulted in the identification of the first reported compounds active on selected E. coli strains. One of the most interesting candidates, compound 86, was shown to inhibit specifically bacterial I,PS heptosylation on efflux pump deleted E. coli strains. This compound did not interfere with E. coli bacterial growth (MIC > 32 mu g/mL) but sensitized this pathogen to hydrophobic antibiotics like macrolides normally inactive on Gram-negative bacteria. In addition, 86 could sensitize E. coli to serum complement killing. These results demonstrate that HldE kinase is a suitable target for drug discovery. They also pave the way toward novel possibilities of treating or preventing bloodstream infections caused by pathogenic Gram negative bacteria by inhibiting specific virulence factors.

  DOI：

  10.1021/jm301499r

文献信息

• New 1,2,4-triazine derivatives and biological applications thereof
  申请人：Mutabilis

  公开号：EP2141164A1

  公开（公告）日：2010-01-06

  The invention relates to new 1,2,4-triazine derivatives of formula (I): wherein A, B, R2 and Y are defined in the application, their preparation and intermediates, their use as drugs and pharmaceutical compositions and associations containing them. The compounds of formula (I) are capable of inhibiting bacterial heptose synthesis.

  这项发明涉及公式(I)的新1,2,4-三嗪衍生物： 其中A、B、R2和Y在申请中有定义， 它们的制备和中间体，它们作为药物和药物组合物的用途以及含有它们的关联物。 公式(I)的化合物能够抑制细菌七糖合成。
• Novel HldE-K Inhibitors Leading to Attenuated Gram Negative Bacterial Virulence
  作者：Nicolas Desroy、Alexis Denis、Chrystelle Oliveira、Dmytro Atamanyuk、Sophia Briet、Fabien Faivre、Géraldine LeFralliec、Yannick Bonvin、Mayalen Oxoby、Sonia Escaich、Stéphanie Floquet、Elodie Drocourt、Vanida Vongsouthi、Lionel Durant、François Moreau、Theodore B. Verhey、Ting-Wai Lee、Murray S. Junop、Vincent Gerusz

  DOI：10.1021/jm301499r

  日期：2013.2.28

  We report here the optimization of an HldE kinase inhibitor to low nanomolar potency, which resulted in the identification of the first reported compounds active on selected E. coli strains. One of the most interesting candidates, compound 86, was shown to inhibit specifically bacterial I,PS heptosylation on efflux pump deleted E. coli strains. This compound did not interfere with E. coli bacterial growth (MIC > 32 mu g/mL) but sensitized this pathogen to hydrophobic antibiotics like macrolides normally inactive on Gram-negative bacteria. In addition, 86 could sensitize E. coli to serum complement killing. These results demonstrate that HldE kinase is a suitable target for drug discovery. They also pave the way toward novel possibilities of treating or preventing bloodstream infections caused by pathogenic Gram negative bacteria by inhibiting specific virulence factors.